Igor Yellson

PHD Doctor of Philosophy,  Mayo Clinic - Rochester 

Location: United States

Consulting Services

Grant Submission Hospital-Pharmacy-Insurance Sales and Marketing Career Advice and Mentoring Pharma-CRO-Device

Areas Of Interest

TB I698 Medial Amygdaloid Nucleus Protein Misfolding Disorders Toxoid, Tetanus TSH beta Sleep Drunkenness Spring, Hot Cell Research, Embryo AI3-24916 Reforms, Health Care Agents, Sympathomimetic FANCE Protein Tumor-Associated Fibroblast Subcutaneous Alternariosis Abuse, Opium KChIP3 Protein Intermediolateral Nucleus INDEL Mutation Rheumox Injuries, Foot Anton's Syndrome gamma Chemokines Cefmetazole Monosodium Salt Angiotensin-Forming Enzyme Tris-Mg(II)-KCl Buffer Iliac Aneurysms beta Ara A LGALS4 Appliance, Fixed Relations, Physician-Hospital Corticotropin-Releasing Factor Oxide, Trichloropropane Culture Medium, Conditioned Avocado Supplementary Feeding Oxidized Cellulose Human papillomavirus 31

Professional Narrative

Dr. Igor Yellson was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Yellson has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.

Employment

Medical Writer, Harvard Med 2013
Executive Director, Mayo Clinic 2001

Education

Master of Science in physician assistant, Weill Medical College 1987
Director Medicine, Baylor College 1989

Referees

Publications

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Erratum in: Ther Deliv. 2016 Jun;7(6):411. PMID: 27075952; PMCID: PMC5439223.

Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021 Nov;178:113834. doi: 10.1016/j.addr.2021.113834. Epub 2021 Sep 4. PMID: 34492233.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. CRISPR- Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014 Oct 9;159(2):440-55. doi: 10.1016/j.cell.2014.09.014. Epub 2014 Sep 25. PMID: 25263330; PMCID: PMC4265475.

Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :

Languages

Language Proficiency :

Translation Services :

Serving Millions of physicians and biomedical scientists in Industry and academia.

Site
Services
Follow Us
Contact Us
  • support@scienceandminds.com

Copyright © 2025 Trialect Inc. All rights reserved. | v2023.06.17.02